Sarepta Therapeutics stock surged by 20 percent after the company brought in much higher-than-expected revenues in its second-quarter earnings report Wednesday. Wall Street believes the biopharmaceutical company's focus on developing treatments for rare neuro-muscular diseases is paying off, putting Sarepta in position to dominate its sector of the...